Revenue was up. Subscribers were up. The stock still fell hard.

That is the kind of reaction you get when expectations are set for clean execution, and the quarter comes with friction.

Hims & Hers reported Q1 2026 revenue of $608.1 million, up from $586.0 million a year earlier. The problem was profitability: the company posted a net loss of $92.1 million, or $(0.40) per diluted share, versus diluted EPS of $0.20 in Q1 2025. Wall Street was looking for roughly $616.5 million of revenue and about $0.01 of EPS. When both lines come in light, it does not take much for positioning to unwind quickly.

The part that matters is what is inside that loss.

A meaningful slice of the damage was tied to the weight loss strategy change. The quarter included $33.5 million of restructuring and related charges tied to the U.S. weight loss offering shift, plus $17.6 million of fair value losses on liabilities and $9.7 million of fair value losses on equity securities. This is not me hand waving it away. Losses count. But it is a different discussion when a large chunk of the loss is transition costs versus the core model suddenly collapsing.

What’s interesting is how fast the industry forced this shift.

Hims benefited from demand for compounded semaglutide during the shortage period. When the FDA determined the semaglutide injection shortage was resolved on February 21, 2025, the window for broad compounding of essentially copy versions narrowed and then closed under the FDA’s wind down timelines. Hims has been working through the aftereffects of that change, moving away from copycat GLP 1 offerings and toward access to FDA approved medications and manufacturer partnerships.

Slight tangent, but it matters: on March 9, 2026, Novo Nordisk dropped its lawsuit against Hims and announced an agreement that will allow Hims customers to access FDA approved Ozempic and Wegovy, including an oral Wegovy option referenced in Novo Nordisk’s statement. That is a real step toward a more durable model. It also makes the near term messy. Switching customers from cheaper compounded options to branded access can pressure demand, marketing spend, and unit economics, all at the same time.

Here’s where I’m at. I care less about the one quarter GAAP loss and more about whether the business can keep its growth profile while the product mix changes.

One encouraging data point: the company generated $89.4 million in operating cash flow in the quarter and ended Q1 with $222.3 million in cash and $528.6 million in short term investments. It is harder to argue “crisis” when operating cash flow is positive and liquidity is still meaningful, even if the income statement looks ugly.

Still, there is a real tension in the operating metrics. Revenue rose about 4% year over year, while subscribers grew about 9%. More subscribers should not usually coincide with that kind of revenue growth gap unless mix or spend per user is shifting. Maybe that is temporary. Maybe it is not. This is the question the next earnings call has to answer in plain English.

Management is also not slowing down on expansion. Hims closed the $153 million YourBio acquisition and announced plans to acquire Eucalyptus for up to $1.15 billion. Big deals can be smart. They can also be a lot to digest when investors are already focused on margin pressure and regulatory scrutiny around weight loss products.

So what should you watch from here?

• Revenue per subscriber and whether the gap between subscriber growth and revenue growth closes.
• Expense control after the restructuring wave, especially if marketing intensity stays elevated.
• Clarity on GLP 1 access, including how the branded pathway affects conversion and retention.
• Cash flow durability if non recurring charges fade but core costs remain higher.

The stock can bounce, it can drift, it can keep sliding. That is not the point. The point is that the company is trying to replace a very profitable growth lever with a more compliant, more sustainable one, and the transition is showing up in the numbers right now.

Next quarter is not a referendum on the long term vision. It is a read on whether the shift is stabilizing, or still getting more complicated.